Department of Obstetrics & Gynecology, St. Marianna University School of Medicine, Kawasaki, Japan.
Department of Obstetrics & Gynecology, Faculty of Medicine, National University of Malaysia, Cheras, Malaysia.
Womens Health (Lond). 2022 Jan-Dec;18:17455057221114269. doi: 10.1177/17455057221114269.
Our review aimed to consolidate the latest update on the application of in vitro maturation among immature oocyte harvest in combination with ovarian tissue cryopreservation known as ovarian tissue oocyte-in vitro maturation.
A thorough search for relevant studies was conducted via PubMed, Google Scholar, EMBASE, and clinical.gov databases up to December 2020. The primary outcome was the oocyte maturation rate, which measured the number of immature oocytes (geminal vesicle stage) that progressed to mature oocytes (meiosis II stage) following in vitro maturation. The secondary outcomes were the fertilization rate following intracytoplasmic sperm injection/in vitro fertilization of these oocytes for the embryo cryopreservation cohort. Our review included pre-pubertal girls and women with cancer who underwent ovarian tissue oocyte-in vitro maturation as fertility preservation.
The primary search identified 207 studies. Twelve manuscripts were selected for inclusion in our review following duplication assessment, title and abstract screening, and full-text evaluation tailored to our inclusion criteria. All the population belonged to a cancer group and underwent concurrent ovarian tissue oocyte-in vitro maturation. A total of 5724 immature oocytes were obtained following ovarian tissue cryopreservation. Approximately 33.84% of the immature oocytes successfully matured via in vitro maturation, which were cryopreserved as oocytes or fertilized as embryos and subsequently stored for future use.
Our review proposed the potential application of ovarian tissue oocyte-in vitro maturation in increasing the number of mature oocytes. The acceptable improvement in oocyte maturation rate following in vitro maturation indicates that improving oocyte outcomes is an excellent cost-effective strategy for fertility preservation among women with cancer.
本综述旨在整合最新的关于不成熟卵母细胞采集与卵巢组织冷冻保存相结合的体外成熟应用的研究进展，即卵巢组织卵母细胞体外成熟。
通过 PubMed、Google Scholar、EMBASE 和 clinical.gov 数据库，对截至 2020 年 12 月的相关研究进行了全面检索。主要结局指标是卵母细胞成熟率，即测量体外成熟后未成熟卵母细胞（生发泡期）向成熟卵母细胞（减数分裂 II 期）的进展数量。次要结局指标是这些卵母细胞进行胞浆内单精子注射/体外受精后胚胎冷冻保存队列的受精率。本综述纳入了接受卵巢组织卵母细胞体外成熟作为生育力保存的青春期前女孩和癌症女性。
初次检索确定了 207 项研究。经过重复评估、标题和摘要筛选以及针对我们纳入标准的全文评估，有 12 篇文献被选入我们的综述。所有人群均属于癌症组，并进行了同期卵巢组织卵母细胞体外成熟。卵巢组织冷冻保存后共获得 5724 个不成熟卵母细胞。大约 33.84%的不成熟卵母细胞通过体外成熟成功成熟，这些卵母细胞被冷冻保存为卵母细胞或受精为胚胎，随后储存以备将来使用。
本综述提出了卵巢组织卵母细胞体外成熟在增加成熟卵母细胞数量方面的潜在应用。体外成熟后卵母细胞成熟率的可接受提高表明，改善卵母细胞结局是癌症女性生育力保存的一种极具成本效益的策略。
